Page last updated: 2024-09-02

ramosetron and Irritable Bowel Syndrome

ramosetron has been researched along with Irritable Bowel Syndrome in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (36.36)29.6817
2010's14 (63.64)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, NM; Brady, CA; Butler, AS; Choo, SH; Cioffi, CL; Cohen, ML; Dobritsa, S; Earley, WG; Fitzpatrick, K; Guo, C; Guzzo, PR; Hassler, C; Manning, DD; Masih, L; Naginskaya, J; Ryan, KN; Sikkander, MI; Usyatinsky, A; Wierschke, JD; Zhang, Z1
Chen, F; Li, Y; Qi, Q; Zhang, Y; Zuo, X1
Barbara, G; Barbaro, MR; De Ponti, F; Dothel, G; Raschi, E1
Akiho, H; Fukudo, S; Ida, M; Matsueda, K; Nakashima, Y1
Camilleri, M; Grover, M1
Hirata, T; Keto, Y; Nakata-Fukuda, M; Uchiyama, Y; Yamano, M; Yokoyama, T1
Haruma, K; Hata, J; Imamura, H; Ishii, M; Kamada, T; Kusunoki, H; Manabe, N; Merchant, JL; Shiotani, A1
Akiho, H; Fukudo, S; Haruma, K; Ida, M; Kinoshita, Y; Nakashima, Y; Nishida, A; Okumura, T1
Akiho, H; Fukudo, S; Haruma, K; Hayashi, K; Ida, M; Kinoshita, Y; Nakashima, Y; Okumura, T1
Morgan, B1
Akiho, H; Fukudo, S; Haruma, K; Hayase, H; Hongo, M; Ida, M; Matsueda, K; Nakashima, Y1
Harasawa, S; Hiwatashi, N; Hongo, M; Matsueda, K; Sasaki, D2
Akiho, H; Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Miyata, K; Nishida, A; Sasamata, M1
Bak, YT; Choi, MK; Choi, SC; Huh, KC; Kim, NY; Kwon, JK; Lee, JS; Lee, KJ; Lee, OY; Myung, SJ; Park, HJ; Rhee, PL; Sohn, CI1
Clavé, P1
Hirata, T; Keto, Y; Seki, N; Sengoku, T; Yamano, M; Yokoyama, T1
Funatsu, T; Hirata, T; Keto, Y; Nakata, M; Sasamata, M1
Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M1
Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A1
Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Miyata, K; Sasamata, M1
den Adel, M; Kadokura, T; Krauwinkel, WJ; Nishida, A; Takeshige, T1

Reviews

4 review(s) available for ramosetron and Irritable Bowel Syndrome

ArticleYear
Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    BMC gastroenterology, 2018, Jan-08, Volume: 18, Issue:1

    Topics: Abdominal Pain; Benzimidazoles; Constipation; Diarrhea; Humans; Irritable Bowel Syndrome; Serotonin 5-HT3 Receptor Antagonists

2018
Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
    Expert opinion on investigational drugs, 2018, Volume: 27, Issue:3

    Topics: Animals; Benzimidazoles; Diarrhea; Drug and Narcotic Control; Drug Design; Gastrointestinal Agents; Humans; Imidazoles; Internationality; Irritable Bowel Syndrome; Phenylalanine

2018
[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2009, Volume: 133, Issue:5

    Topics: Animals; Benzimidazoles; Clinical Trials as Topic; Diarrhea; Dose-Response Relationship, Drug; Humans; Irritable Bowel Syndrome; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Stress, Psychological

2009
Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
    Inflammopharmacology, 2007, Volume: 15, Issue:1

    Topics: Abdominal Pain; Animals; Benzimidazoles; Defecation; Diarrhea; Dogs; Gastrointestinal Transit; Humans; Irritable Bowel Syndrome; Mice; Models, Animal; Rats; Serotonin Antagonists

2007

Trials

7 trial(s) available for ramosetron and Irritable Bowel Syndrome

ArticleYear
Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:6

    Topics: Administration, Oral; Adult; Animals; Benzimidazoles; Chemical Phenomena; Diarrhea; Double-Blind Method; Feces; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Japan; Male; Middle Aged; Placebos; Rats; Treatment Outcome; Young Adult

2014
Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Gastroenterology, 2016, Volume: 150, Issue:2

    Topics: Adult; Benzimidazoles; Constipation; Diarrhea; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Japan; Middle Aged; Prospective Studies; Quality of Life; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Sex Factors; Time Factors; Treatment Outcome; Young Adult

2016
Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
    Journal of gastroenterology, 2016, Volume: 51, Issue:9

    Topics: Adult; Benzimidazoles; Diarrhea; Drug Administration Schedule; Female; Humans; Irritable Bowel Syndrome; Middle Aged; Serotonin Antagonists; Treatment Outcome

2016
Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Neurogastroenterology and motility, 2017, Volume: 29, Issue:6

    Topics: Abdominal Pain; Adult; Benzimidazoles; Diarrhea; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Middle Aged; Serotonin Antagonists; Treatment Outcome

2017
A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Scandinavian journal of gastroenterology, 2008, Volume: 43, Issue:10

    Topics: Adult; Benzimidazoles; Diarrhea; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Japan; Male; Middle Aged; Serotonin Antagonists; Treatment Outcome

2008
A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
    Digestion, 2008, Volume: 77, Issue:3-4

    Topics: Adult; Asian People; Benzimidazoles; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Japan; Male; Serotonin Antagonists; Treatment Outcome

2008
Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Neurogastroenterology and motility, 2011, Volume: 23, Issue:12

    Topics: Adolescent; Adult; Benzimidazoles; Diarrhea; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Parasympatholytics; Phenethylamines; Republic of Korea; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Young Adult

2011

Other Studies

11 other study(ies) available for ramosetron and Irritable Bowel Syndrome

ArticleYear
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
    Bioorganic & medicinal chemistry letters, 2011, Jan-01, Volume: 21, Issue:1

    Topics: Animals; Cell Line; Disease Models, Animal; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Mice; Microsomes, Liver; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Agonists

2011
Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:6

    Topics: Animals; Benzimidazoles; Chemical Phenomena; Diarrhea; Feces; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Male

2014
Inhibitory effect of the selective serotonin 5-HT₃ receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats.
    European journal of pharmacology, 2014, May-15, Volume: 731

    Topics: Animals; Benzimidazoles; Biguanides; Duodenum; Hydrogen-Ion Concentration; Irritable Bowel Syndrome; Male; Nociception; Quinolizines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists; Stomach

2014
Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
    Neurogastroenterology and motility, 2015, Volume: 27, Issue:1

    Topics: Adult; Annexin A2; Benzimidazoles; Biomarkers, Pharmacological; Diarrhea; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; S100 Proteins; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Tryptophan Hydroxylase

2015
Drug development: A healthy pipeline.
    Nature, 2016, 05-19, Volume: 533, Issue:7603

    Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; Colestipol; Disease Models, Animal; Enteric Nervous System; Female; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Loperamide; Lubiprostone; Male; Mice; Natriuretic Peptides; Peptides; Phenylalanine; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Rifamycins; Rifaximin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Visceral Pain

2016
Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets.
    Neurogastroenterology and motility, 2011, Volume: 23, Issue:12

    Topics: Benzimidazoles; Diarrhea; Humans; Irritable Bowel Syndrome; Male; Parasympatholytics; Phenethylamines; Serotonin 5-HT3 Receptor Antagonists

2011
Inhibitory effect of ramosetron on corticotropin releasing factor- and soybean oil-induced delays in gastric emptying in rats.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:9

    Topics: Animals; Antidiarrheals; Benzamides; Benzimidazoles; Benzyl Compounds; Biguanides; Corticotropin-Releasing Hormone; Dyspepsia; Fenclonine; Gastric Emptying; Irritable Bowel Syndrome; Male; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Soybean Oil

2012
Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
    Journal of pharmacological sciences, 2007, Volume: 104, Issue:3

    Topics: Animals; Benzimidazoles; Carbazoles; Carbolines; Carrier Proteins; Colon; Defecation; Gastrointestinal Agents; Guinea Pigs; Humans; Ion Channels; Irritable Bowel Syndrome; Loperamide; Male; Muscle, Smooth; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Restraint, Physical; Serotonin Antagonists; Stress, Psychological

2007
Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    European journal of pharmacology, 2007, Nov-14, Volume: 573, Issue:1-3

    Topics: Animals; Behavior, Animal; Benzimidazoles; Carbazoles; Carbolines; Colon; Colonic Diseases, Functional; Conditioning, Psychological; Corticotropin-Releasing Hormone; Defecation; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Gastrointestinal Transit; Immobilization; Irritable Bowel Syndrome; Loperamide; Male; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Stress, Psychological; Time Factors; Treatment Outcome

2007
Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.
    Journal of pharmacological sciences, 2008, Volume: 106, Issue:2

    Topics: Animals; Antidiarrheals; Benzimidazoles; Conditioning, Classical; Defecation; Fear; Irritable Bowel Syndrome; Loperamide; Male; Parasympatholytics; Quinolizines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Stress, Physiological; Trimebutine

2008
The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.
    European journal of clinical pharmacology, 2008, Volume: 64, Issue:7

    Topics: Adult; Area Under Curve; Benzimidazoles; Cross-Over Studies; Drug Interactions; Female; Fluvoxamine; Half-Life; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Quality of Life; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists

2008